I5X Stock Overview
Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.82 |
| 52 Week High | US$1.80 |
| 52 Week Low | US$0.71 |
| Beta | 1.68 |
| 11 Month Change | 3.13% |
| 3 Month Change | -14.54% |
| 1 Year Change | -14.72% |
| 33 Year Change | -75.40% |
| 5 Year Change | -84.50% |
| Change since IPO | -94.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| I5X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -1.9% | -0.6% |
| 1Y | -14.7% | -18.1% | 9.6% |
Return vs Industry: I5X exceeded the German Biotechs industry which returned -18.7% over the past year.
Return vs Market: I5X underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| I5X volatility | |
|---|---|
| I5X Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I5X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I5X's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
| I5X fundamental statistics | |
|---|---|
| Market cap | €250.90m |
| Earnings (TTM) | -€128.77m |
| Revenue (TTM) | €4.17m |
57.9x
P/S Ratio-1.9x
P/E RatioIs I5X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I5X income statement (TTM) | |
|---|---|
| Revenue | US$4.39m |
| Cost of Revenue | US$59.50m |
| Gross Profit | -US$55.11m |
| Other Expenses | US$80.27m |
| Earnings | -US$135.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | -1,255.73% |
| Net Profit Margin | -3,084.55% |
| Debt/Equity Ratio | 0% |
How did I5X perform over the long term?
See historical performance and comparison